— Experienced Executive Brings Over Twenty Years of Global Financial Leadership to Amarin —
— Michael W. Kalb leaves Amarin to pursue other interests —
DUBLIN, Ireland and BRIDGEWATER, NJ, June 06, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022. This appointment follows the resignation of Michael W. Kalb who will leave the Company to pursue other interests after a brief transition period.
“We are delighted to welcome Tom Reilly to the Amarin management team. Tom’s significant financial leadership experience in large global pharmaceutical and biotechnology companies, as well as his proven track record in financial planning and analysis within international and commercial operations will be a great asset to Amarin as we are expanding all over the world. I look forward to working closely with Tom to achieve our European and international goals,” said Karim Mikhail, President and CEO of Amarin. “I would like to thank Mike for his years of service to Amarin. On behalf of the entire Amarin team, I wish him much success in his future endeavours.
“Tom’s appointment illustrates our commitment to strengthening our leadership team and Board of Directors with the right talent to support the company’s BOLD vision to prevent cardiovascular disease from being a leading cause of death worldwide” , concluded Mr. Mikhail.
“I am delighted to join Amarin at this important stage in the company’s global expansion, and look forward to applying my experience in executing disciplined financial management and leadership that will support growth. of the company in the years to come,” Mr. Reilly said.
Tom Reilly is an experienced senior executive with significant corporate and commercial finance expertise in the pharmaceutical and biotechnology industries. Most recently, he served as Chief Financial Officer of Cara Therapeutics, where he was responsible for directing all aspects of Cara’s financial operations and planning. Prior to this role at Cara, Mr. Reilly served as Head of Finance for Allergan’s US General Medicines unit, where he led all financial management for that company. Prior to Allergan, Mr. Reilly spent 14 years at Novartis where he held positions of increasing responsibility, including Chief Financial Officer of Novartis Oncology Development Unit, Chief Financial Officer of Novartis Pharma Austria, Financial Controller of Novartis Pharmaceuticals Division USA as well as a series of roles supporting financial planning and analysis and accounting for Novartis. Earlier in his career, Mr. Reilly held financial planning and finance positions at Pharmacia.
Mr. Reilly holds a Bachelor of Science in Finance from Manhattan College and an MBA in Accounting from Seton Hall University.
Amarin is an innovative pharmaceutical company at the forefront of a new paradigm in the management of cardiovascular disease. From our scientific research base, to our focus on clinical trials, and now to our global business expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the USA, Dublin in Ireland, Zug in Switzerland and other countries in Europe, as well as business partners and suppliers worldwide. We are committed to rethinking cardiovascular risk by advancing scientific understanding of the societal impact of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Availability of other information about Amarin
Amarin communicates with its investors and the public using the company’s website (www.amarincorp.com) and Investor Relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission (“SEC”) filings , press releases, public conference calls and webcasts. Information posted by Amarin on these channels and websites could be considered material information. Accordingly, Amarin encourages investors, the media and others interested in Amarin to regularly review the information posted on these channels, including the Investor Relations website. This list of channels may be updated from time to time on the Amarin Investor Relations website and may include social media channels. The content of Amarin’s website or such channels, or any other website accessible from its website or such channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
This press release contains forward-looking statements within the meaning of United States securities laws. These forward-looking statements are neither promises nor guarantees and involve substantial risks and uncertainties. A list and description of such risks, uncertainties and other risks associated with an investment in Amarin may be found in Amarin’s filings with the SEC, including Amarin’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date to which they are made. Amarin undertakes no obligation to update or revise any information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of material transactions that the company may enter into, such as mergers, acquisitions, divestitures, joint ventures or any material agreements that Amarin may enter into, modify or terminate.
Lisa De Francesco
Investor Relations Amarin Corporation plc
[email protected] (investor enquiries)
Corporate Communications, Amarin Corporation plc
[email protected] (media inquiries)